← Back to results
Federal

MERIT Act

Source: Congress.gov  ·  577 words in original text
What This Bill Does
This bill changes how Medicare decides whether to cover individual drugs and biological products. The bill requires Medicare to review each drug or biological product separately rather than reviewing entire groups of similar drugs at the same time.
Who It Affects
Medicare beneficiaries (people covered by Medicare) and drug manufacturers whose products Medicare reviews for coverage.
Key Provisions
• Medicare must evaluate each drug or biological product individually to determine if it is reasonable and necessary for Medicare to cover, rather than evaluating groups or classes of drugs together (Sec. 2)
What Changes
Starting from when this bill becomes law, Medicare's coverage decisions about whether to pay for drugs or biological products must be made one drug at a time instead of reviewing multiple drugs in the same drug class together.
Important Definitions
The bill does not explicitly define "reasonable and necessary," "drug," "biological," or "drug class," though it uses these terms.
Effective Date
Not specified in bill text
Important: This plain English summary was generated by AI and is provided for informational purposes only. It is not legal advice. Always consult the official bill text on Congress.gov or a qualified attorney for legal matters.